Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Diphosphate SCHEMBL29395812 | 1.00 | CYP3A4 (0.77) | CYP3A4CYP2D6 | |
| Tenofovir Diphosphate SCHEMBL29466912 | 1.00 | CYP3A4 (0.77) | CYP3A4CYP2D6 | |
| Tenofovir Diphosphate SCHEMBL24809661 | 1.00 | CYP3A4 (0.77) | CYP3A4CYP2D6 | |
| SCHEMBL14440381 | 0.96 | CYP3A4 (0.80) | CYP3A4CYP2D6 | |
| SCHEMBL24809662 | 0.96 | CYP3A4 (0.80) | CYP3A4CYP2D6 | |
| SCHEMBL19600198 | 0.94 | CYP3A4 (0.77) | CYP3A4CYP2D6 | |
| SCHEMBL20313254 | 0.92 | CYP3A4 (0.74) | CYP3A4CYP2D6 | |
| SCHEMBL13394187 | 0.91 | CYP3A4 (0.75) | CYP3A4CYP2D6 | |
| SCHEMBL20321881 | 0.90 | CYP3A4 (0.71) | CYP3A4CYP2D6 | |
| Tenofovir Anhydrous SCHEMBL400717 | 0.89 | CYP3A4 (0.91) | CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334743-B1 | ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11826375-B2 | Phosphinic amide prodrugs of tenofovir | MERCK SHARP & DOHME LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826375-B2 | Phosphinic amide prodrugs of tenofovir | MERCK SHARP & DOHME LLC (US) | 2023-11-28 | — | — | US | disclosed |
| EP-3386512-B1 | ANTIVIRAL PHOSPHODIAMIDE PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022271880-A1 | METHODS OF TREATING MEDICAL CONDITIONS AND INHIBITING LINE1 REVERSE TRANSCRIPTASE USING A SUBSTITUTED ADENINYL-PROPYLOXY PHOSPHONIC ACID OR RELATED COMPOUND | ROME THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-3559011-B1 | ANTIVIRAL ESTER PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11123355-B2 | Antiviral benzyl-amine phosphodiamide compounds | IDENIX PHARMACEUTICALS LLC (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3390413-B1 | ANTIVIRAL OXIME PHOSPHORAMIDE COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10745428-B2 | Antiviral phosphodiamide prodrugs of tenofovir | IDENIX PHARMACEUTICALS LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-10736908-B2 | Antiviral aryl-amide phosphodiamide compounds | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| EP-2579871-B1 | TOPICAL ANTIVIRAL FORMULATIONS FOR PREVENTION OF TRANSMISSION OF HSV-2 | GILEAD SCIENCES INC (US) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014088923-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20130216590-A1 | TOPICAL ANTIVIRAL FORMULATIONS FOR PREVENTION OF TRANSMISSION OF HSV-2 | GILEAD SCIENCES, INC. | 2013-08-22 | — | — | US | disclosed |
| US-20130216590-A1 | TOPICAL ANTIVIRAL FORMULATIONS FOR PREVENTION OF TRANSMISSION OF HSV-2 | GILEAD SCIENCES, INC. | 2013-08-22 | — | — | US | disclosed |
| US-20130216590-A1 | TOPICAL ANTIVIRAL FORMULATIONS FOR PREVENTION OF TRANSMISSION OF HSV-2 | GILEAD SCIENCES, INC. | 2013-08-22 | — | — | US | disclosed |
| EP-2579871-A1 | TOPICAL ANTIVIRAL FORMULATIONS FOR PREVENTION OF TRANSMISSION OF HSV-2 | Gilead Sciences, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20070281911-A1 | Use of Adefovir or Tenofovir for Inhibiting Mmtv-Like Viruses Involved in Breast Cancer and Primary Biliary Cirrhosis | GILEAD SCIENCES INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736908-B2 | Antiviral aryl-amide phosphodiamide compounds | PNP, TYMP, DUT | CYP3A4 1082/4885CYP2D6 1883/4885 |
| US-11123355-B2 | Antiviral benzyl-amine phosphodiamide compounds | TYMP, PNP, POLI | CYP3A4 2278/4885CYP2D6 3727/4885 |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | DCK, DTYMK, TK1 | CYP3A4 1852/4885CYP2D6 1377/4885 |
| US-10745428-B2 | Antiviral phosphodiamide prodrugs of tenofovir | PNP, TYMP, PPA1 | CYP3A4 628/4885CYP2D6 1334/4885 |
| US-20130216590-A1 | TOPICAL ANTIVIRAL FORMULATIONS FOR PREVENTION OF TRANSMISSION OF HSV-2 | PRPH, TK1, PLP2 | CYP3A4 4002/4885CYP2D6 1734/4885 |
| US-11826375-B2 | Phosphinic amide prodrugs of tenofovir | TYMP, PPA1, PNP | CYP3A4 1743/4885CYP2D6 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.